Equity Overview
Price & Market Data
Price: $1.91
Daily Change: -$0.015 / 0.79%
Daily Range: $1.83 - $1.97
Market Cap: $70,991,208
Daily Volume: 197,859
Performance Metrics
1 Week: -16.00%
1 Month: -14.48%
3 Months: 18.87%
6 Months: -28.41%
1 Year: -50.00%
YTD: -47.65%
Company Details
Employees: 202
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.